Supporting Information For

Synthesis and evaluation of anticancer activities of novel C-28 guanidine-functionalized triterpene acid derivatives.


Institute of Petrochemistry and Catalysis, Russian Academy of Sciences, 141 prosp. Oktyabrya, 450075 Ufa, Russian Federation

E-mail:* spivak.ink@gmail.com

Index

<table>
<thead>
<tr>
<th>Index</th>
<th>Page Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 4</td>
<td>3</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 5</td>
<td>5</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 6</td>
<td>7</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 7</td>
<td>9</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 8a</td>
<td>11</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 15</td>
<td>13</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 18</td>
<td>15</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 19</td>
<td>17</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 20</td>
<td>19</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 21</td>
<td>21</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 9</td>
<td>23</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 10</td>
<td>25</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 11</td>
<td>27</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 12</td>
<td>29</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 13</td>
<td>31</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 15a</td>
<td>33</td>
</tr>
<tr>
<td>(^1)H, (^{13})C NMR of Compound 18a</td>
<td>35</td>
</tr>
<tr>
<td>Compound</td>
<td>NMR Spectroscopy</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------</td>
</tr>
<tr>
<td>20a</td>
<td>$^1$H, $^{13}$C NMR</td>
</tr>
<tr>
<td>9a</td>
<td>$^1$H, $^{13}$C, $^{19}$F NMR</td>
</tr>
<tr>
<td>10a</td>
<td>$^1$H, $^{13}$C, $^{19}$F NMR</td>
</tr>
<tr>
<td>11a</td>
<td>$^1$H, $^{13}$C, $^{19}$F NMR</td>
</tr>
<tr>
<td>12a</td>
<td>$^1$H, $^{13}$C, $^{19}$F NMR</td>
</tr>
<tr>
<td>13a</td>
<td>$^1$H, $^{13}$C, $^{19}$F NMR</td>
</tr>
<tr>
<td>15b</td>
<td>$^1$H, $^{13}$C, $^{19}$F NMR</td>
</tr>
<tr>
<td>18b</td>
<td>$^1$H, $^{13}$C, $^{19}$F NMR</td>
</tr>
<tr>
<td>20b</td>
<td>$^1$H, $^{13}$C, $^{19}$F NMR</td>
</tr>
<tr>
<td>9b</td>
<td>$^1$H, $^{13}$C NMR</td>
</tr>
<tr>
<td>10b</td>
<td>$^1$H, $^{13}$C NMR</td>
</tr>
<tr>
<td>11b</td>
<td>$^1$H, $^{13}$C NMR</td>
</tr>
<tr>
<td>12b</td>
<td>$^1$H, $^{13}$C NMR</td>
</tr>
<tr>
<td>15c</td>
<td>$^1$H, $^{13}$C NMR</td>
</tr>
<tr>
<td>18c</td>
<td>$^1$H, $^{13}$C NMR</td>
</tr>
<tr>
<td>20c</td>
<td>$^1$H, $^{13}$C NMR</td>
</tr>
<tr>
<td>14</td>
<td>$^1$H, $^{13}$C NMR</td>
</tr>
</tbody>
</table>
N-(4-aminobuty1)-3-oxolupane-28-amide (4). $^1$H NMR spectra (CDCl$_3$)
N-(4-aminobuthyl)-3-oxolupane-28-amide (4). $^{13}$C NMR spectra (CDCl$_3$)
3β-N-(2-aminoethyl)-3-O-acetyl-lupane-28-amide (5). $^1$H NMR spectra (CDCl$_3$)
$3\beta$-N-(2-aminoethyl)-3-O-acetyl-lupane-28-amide (5). $^{13}$C NMR spectra (CDCl$_3$)
3β-N-(4-aminobuthyl)-3-O-acetyl-lupane-28-amide (6) $^1$H NMR spectra (CDCl$_3$)
3β-N-(4-aminobuthyl)-3-O-acetyl-lupane-28-amide (6) $^{13}$C NMR spectra (CDCl$_3$)
3β-N-[2-(N,N’-bis-aminoethyl)-aminoethyl]-3-O-acetyl-lupane-28-amide (7).

\[\text{1H NMR spectra (MeOD)}\]
3β-N-[2-(N,N'-bis-aminoethyl)-aminoethyl]-3-O-acetyl-lupane-28-amide (7).

$^{13}$C NMR spectra (MeOD)

$^1$H NMR spectra (CDCl$_3$)
3β-N-[(3-(3-aminopropyl)piperazinyl)propyl]-3-O-acetyl-lupane-28-amide (8a).

$^{13}$C NMR spectra (CDCl$_3$)
3β-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-lupane-28-oate (15).

\[^{1}H\text{NMR spectra (CDCl}_3\)]
3β-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-lupane-28-oate (15).

$^{13}$C NMR spectra (CDCl$_3$)
3β-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyltus-12-en-28-oate (18).

$^1$H NMR spectra (CDCl$_3$)
3β-[2-amino-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyls-12-en-28-oate (18).

$^{13}$C NMR spectra (CDCl$_3$)
$3\beta$-N-[(1',1',1'-tris-hidroxymethyl)methyl]-3-O-acetyl-ursolamide (19)

$^1$H NMR spectra (MeOD)
3β-N-[(1',1',1'-tris-hidroxymethyl)methyl]-3-O-acetyl-ursolamide (19)

$^{13}$C NMR spectra (d5-DMSO)
3β-[2-amino-3-hydroxy-2(hydroxymethyl)propyl]-3-O-acetylolean-12-en-28-oate (20).

$^1$H NMR spectra (CDCl$_3$)
3β-[2-amino-3-hydroxy-2(hydroxymethyl)propyl]-3-O-acetylolean-12-en-28-oate (20).

$^{13}$C NMR spectra (CDCl$_3$)
3β-N-[(1',1',1'-tris-hidroxymethyl)methyl]-3-O-acetyl-oleanolamide (21)

$^1$H NMR spectra (d$_6$-DMSO)
3β-N-[(1',1',1'-tris-hidroxymethyl)methyl]-3-O-acetyl-oleanolamide (21)

$^{13}$C NMR spectra (d$_6$-DMSO)
N-[4-tert-butyloxy carbonyl butyl guanidine]-3-oxo-lupane-28-amide (9)

\(^1\)H NMR spectra (CDCl\(_3\))
N-[4-tert-butyloxycarbonyl butylguanidine]-3-oxo-lupane-28-amide (9)

$^{13}$C NMR spectra (CDCl$_3$)
3β-N-(2-tert-butyloxycarbonyl ethylguanidine)-3-O-acetyl-lupane-28-amide (10).

$\text{H} N\text{MR spectra (CDCl}_3\text{)}$
3β-N-(2-tert-butyloxycarbonyl ethylguanidine)-3-O-acetyl-lupane-28-amide (10).

$^{13}$C NMR spectra (CDCl$_3$)
3β-N-[4-tert-butyloxy carbonyl butylguanidine]-3-O-acetyl-lupane-28-amide (11).

$^1$H NMR spectra (CDCl$_3$)
3β-N-[4-tert-butyloxycarbonyl buthylguanidine]-3-O-acetyl-lupane-28-amide (11).

$^{13}$C NMR spectra (CDCl$_3$)
3β-N-[2-(N,N'-bis-tert-butyloxycarbonyl ethylglyanidine)-aminoethyl]-3-O-acetyl-lupane-28-amide (12). $^1$H NMR spectra (CDCl$_3$)
3β-N-[2-(N,N'-bis-tert-butyloxycarbonyl ethylganyline)-aminoethyl]-3-O-acetyl-lupane-28-amide (12). $^{13}$C NMR spectra (CDCl$_3$)
3β-N-[(3-(3-tert-butoxycarbonyl propyl)gynidine)piperazinyl]propyl]-3-O-acetyl-lupane-28-amide (13). $^1$H NMR spectra (CDCl$_3$)
3β-N-[[3-(3-tert-butyloxycarbonyl propyl)glycinyl]propyl]-3-O-acetyl-lupane-28-
amide (13). $^{13}$C NMR spectra (CDCl$_3$)
$3\beta$-[2-tert-butyloxycarbonylguanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-lupane-28-oate (15a). $^1$H NMR spectra (CDCl$_3$)
$3\beta$-[2-tert-butyloxycarbonylguanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-lupane-28-oate (15a). $^{13}$C NMR spectra (CDCl$_3$)
3β-[2-tert-butoxy carbonyl guanidine-3-hydroxy-2-(hydroxymethyl) propyl]-3-O-acetyl urs-12-en-28-oate (18a). $^1$H NMR spectra (CDCl$_3$)
3β-[2-tert-butyloxycarbonylguanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-urs-12-en-28-oate (18a). $^{13}$C NMR spectra (CDCl$_3$)
3β-[2-tert-butyloxycarbonylguanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-olean-12-en-28-oate (20a). $^1$H NMR spectra (CDCl$_3$)
3β-[2-tert-butyloxycarbonylguanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl - olean-12-en-28-oate (20a). $^{13}$C NMR spectra (CDCl$_3$)
N-(4-buthylglyanidine)-3-oxolupane-28-amide trifluoroacetate (9a). $^1$H NMR spectra (CDCl$_3$)
N-(4-buthylganydine)-3-oxolupane-28-amide trifluoroacetate (9a). $^{13}$C NMR spectra (CDCl$_3$)
N-(4-buthylgyanidine)-3-oxolupane-28-amide trifluoroacetate (9a). $^{19}$F NMR spectra (CDCl$_3$)
3β-N-(2-ethylgynidine)-3-O-acetyl-lupane-28-amide trifluoroacetate (10a). $^1$H NMR spectra (CDCl$_3$)
3β-N-(2-ethylgynidine)-3-O-acetyl-lupane-28-amide trifluoroacetate (10a). $^{13}$C NMR spectra (CDCl$_3$)
3β-N-(2-ethylgynidine)-3- O-acetyl-lupane-28-amide trifluoroacetate (10a). $^{13}$F NMR spectra (CDCl$_3$)
3β-N-(4-buthylganyamidine)-3-O-acetyl-lupane-28-amide trifluoroacetate (11a). $^1$H NMR spectra (MeOD)
3β-N-(4-buthylgyanidine)-3- O-acetyl-lupane-28-amide trifluoroacetate (11a). $^{13}$C NMR spectra (MeOD)
$3\beta$-N-(4-buthylganydine)-3- O-acetyl-lupane-28-amide trifluoroacetate (11a). $^{19}$F NMR spectra (MeOD)
3β-N-[2-(N,N'-bis-ethylganydine)-ethyl]-3-O-acetyl-lupane-28-amide trifluoroacetate (12a)

$^{1}$H NMR spectra (MeOD)
3β-N-[2-(N,N’-bis-ethylglyanidine)-ethyl]-3- O-acetyl -lupane-28-amide trifluoroacetate (12a).

$^{13}$C NMR spectra (MeOD)
3β-N-[2-(N,N'-bis-ethylcyanidine)-ethyl]-3-O-acetyl-lupane-28-amide trifluoroacetate (12a).

$^{19}$F NMR spectra (MeOD)
$3\beta$-N-$\{[3-(3\text{-propylguanidine})\text{piperazinyl}]{propyl}\}$-3-O-acetyl-lupane-28-amide trifluoroacetate (13a).

$^1$H NMR spectra (MeOD)

$^{13}$C NMR spectra (MeOD)
3β-N-[(3-(3-propylguanidine)piperazinyl)propyl]-3-O-acetyl-lupane-28-amide trifluoroacetate (13a).

$^{19}$F NMR spectra (MeOD)
$3\beta$-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-lupane-28-oate trifluoroacetate (15b). $^1$H NMR spectra (CDCl$_3$)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-lupane-28-oate trifluoroacetate (15b). $^{13}$C NMR spectra (CDCl$_3$)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-lupane-28-oate trifluoroacetate (15b). $^{19}$F NMR spectra (CDCl$_3$)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-urs-12-en-28-oate trifluoroacetate (18b). $^1$H NMR spectra (MeOD)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-urs-12-en-28-oate trifluoroacetate (18b). $^{13}$C NMR spectra (MeOD)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-urs-12-en-28-oate trifluoroacetate (18b). $^{19}$F NMR spectra (MeOD)
$3\beta$-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-olean-12-en-28-oate trifluoroacetate (20b). $^1$H NMR spectra (MeOD)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-olean-12-en-28-oate trifluoroacetate (20b). $^{13}$C NMR spectra (MeOD)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-olean-12-en-28-oate trifluoroacetate (20b). $^{19}$F NMR spectra (MeOD)
N-(4-buthylglyanidine)-3-oxolupane-28-amide dihydrochloride (9b).

$^1$H NMR spectra ($d_6$-DMSO)
N-(4-buthylgyanidine)-3-oxolupane-28-amide dihydrochloride (9b).

$^{13}$C NMR spectra (d$_6$-DMSO)
3β-N-(2-ethylgyanidine)-3-O-acetyl-lupane-28-amide hydrochloride (10b).

$^1$H NMR spectra (MeOD)
3β-N-(2-ethylgynadine)-3-O-acetyl-lupane-28-amide hydrochloride (10b).

$^1$H NMR spectra (MeOD)
3β-N-(4-buthylgyanidine)-3-O-acetyl-lupane-28-amide hydrochloride (11b).

$^1$H NMR spectra (MeOD)
3β-N-(4-buthylgyanidine)-3-O-acetyl-lupane-28-amide hydrochloride (11b).

$^{13}$C NMR spectra (MeOD)
3β-N-[2-(N,N'-bis-ethylglyanidine)-ethyl]-3-O-acetyl-lupane-28-amide dihydrochloride (12b).

$^1$H NMR spectra (MeOD)
3β-N-[2-(N,N’-bis-ethylglycine)]-3-O-acetyl-lupane-28-amide dihydrochloride (12b).

$^{13}$C NMR spectra (MeOD)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-lupane-28-oate hydrochloride (15c). $^1$H NMR spectra (MeOD)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-lupane-28-oate hydrochloride (15e). $^{13}$C NMR spectra (MeOD)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-urs-12-en-28-oate hydrochloride (18c). $^1$H NMR spectra (MeOD)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-urs-12-en-28-oate hydrochloride (18c). $^{13}$C NMR spectra (MeOD)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-olean-12-en-28-oate hydrochloride (20c). \(^1\)H NMR spectra (MeOD)
3β-[2-guanidine-3-hydroxy-2-(hydroxymethyl)propyl]-3-O-acetyl-olean-12-en-28-oate hydrochloride (20c). $^{13}$C NMR spectra (MeOD)
3β-N-(4-buthylgyanidine)-3-hydroxy-lupane-28-amide (14).

\(^1\)H NMR spectra (d\(_6\)-DMSO)
3β-N-(4-buthylgyanidine)-3-hydroxy-lupane-28-amide (14).

$^{13}$C NMR spectra (d$_6$-DMSO)